Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes

NCT07173712 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

324

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: CSII
DRUG: Insulin glargine /lixisenatide Fixed Ratio Combination
DRUG: Insulin Degludec and Insulin Aspart Injection
DRUG: Insulin Glargine (HOE901 - U300)
DRUG: Metformin

Sponsor

Yanbing Li